Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Circulogene Licenses Liquid Biopsy Tech to Turkish Lab

Circulogene Licenses Liquid Biopsy Tech to Turkish Lab

Jan 03, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Circulogene announced today that it has signed a license agreement for its molecular cancer diagnostic technology with Turkish lab Circulogene Saglik, a subsidiary of GGT Global Genetik.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

What's Popular?

In Sequencing

  1. Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

    Premium

  2. UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal

  3. JP Morgan Downgrades Illumina to Neutral on Grail Deal

  4. Illumina to Acquire Grail for $8B in Cash and Stock

  5. Genosity Inks Comarketing Agreement with Personal Genome Diagnostics

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.